Heart Failure in Norway: Clinical Characteristics, Mortality and Health Care Resource Use

NCT ID: NCT04398563

Last Updated: 2020-05-21

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 14998 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-01-20
• Study Completion Date: 2023-12-31

Brief Summary

The prevalence of Heart failure above 70 years of age is 10% and 5 year mortality rate above 60%, higher than for cancer. The readmission rate first after hospitalisation is 44% despite the availability of life prolonging and life quality enhancing treatment. There is a lack of resources for adequate diagnostic workup necessary for implementing evidence-based treatment. This projects aims at assessing the impact of guidelines based diagnostic workup and guidelines based treatment of heart failure on mortality and readmission rates. As the symptoms defining the degree of heart failure and the discharge medication only is available in the electronic patient files, artificial intelligence is used to retrieve this information to assess if treatment is according to guidelines.

The project is using first a rule based text processing approach using IBM Watson, then advancing to a machine learning approach using readmission and mortality as endpoints.

The project has access to digitally stored echocardiographic measurements as well as digital ECG's and lab data on 15 000 patients admitted with a diagnosis of Heart failure. If the retrieval of symptoms and function by artificial intelligence is successful, the next step is to assess if those benefitting the most from echocardiography can be identified using information from the ECG's, lab data or symptoms and functional capacity as described in the Electronic Health Records.

Conditions

Heart Failure; Heart Failure With Preserved Ejection Fraction; Heart Failure With Reduced Ejection Fraction

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

In addition all subjects with NT-proBNP above age specific normal range in same period.

Exclusion Criteria

none

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

University Hospital, Akershus

OTHER

Sponsor Role: lead

Responsible Party

Torbjorn Omland

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Henrik Schirmer, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Akershus

Locations

Akershus University Hospital

Lørenskog, , Norway

Countries

Norway

Other Identifiers

2019/833 (REK)

Identifier Type: -

Identifier Source: org_study_id